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ease progression. Real-world data on actual health care resource consumption and
patient clinical characteristics are used. Time horizon of themodels should be long
enough to capture meaningful differences in outcomes. The differential clinical
attributes of the products are identified and direct links are established with the
corresponding economic values. The resulting impact on disease progression and
consequences for consumption of health care resources are simulated. The pri-
mary output is the cost-avoidance against the chosen comparator, with corre-
sponding breakdown by each clinical attribute. RESULTS: CCEV directly translates
the differences in clinical outcomes to the differences in economic values. This
methodology has been effectively applied in the decision process at different
stages of drug development, such as, to prioritize pipeline assets by comparing the
potential economic value of assets under development and quantifying the value
of each differentiated output. These insights are used to guide and design the
following data generation strategies. CONCLUSIONS: CCEV methodology directly
translates clinical outcomes to economic values and is a practical PE tool for deci-
sion makers. It can be employed across the entire product life-cycle, starting from
the early stages of drug development.
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ARE MINIMAL CLINICALLY IMPORTANT DIFFERENCE MEASURES (MCIDS)
RELEVANT FOR SURVIVAL OUTCOMES? INTRODUCING THE MCID-CAC
Standfield L, Weston A
OptumInsight, Sydney, NSW, Australia
Minimal Clinically Important Difference margins (MCIDs) are being applied by re-
imbursement agencies to assess the non-inferiority of new medications against
comparator medications in the Asia Pacific Region. If a new medication is deemed
non-inferior to an all ready reimbursed medication either via direct or indirect
comparison methods the newer product is generally reimbursed at the same price
as the comparator medication (ie. through cost-minimisation). The concept of an
MCID margin for survival outcomes, however, is problematic and controversial. A
superficial consideration of MCIDs for survival outcomes may lead to the conclu-
sion that the MCID for survival is inappropriate and no difference in survival is
acceptable. As such, the MCID for survival should be zero. In this case such an
analysis would become a superiority analysis. If this approach to the assessment of
such products were to prevail, new products with a high likelihood of affording
patients a survival benefit compared to their comparator products may be rejected
even on a cost-minimisation basis. Instead, where the point estimate of treatment
effect favours the new treatment serious consideration should be given to reim-
bursing the new product at the same or higher price. Using indirect comparison
methods and real world hazard ratio data this research introduces the concept of
MCID-cumulative acceptability curves (MCID-CAC) as an aid to making pragmatic
reimbursement decisions for new products that may extend patients lives.
DISEASE-SPECIFIC STUDIES
CANCER-Clinical Outcomes Studies
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BISPHOSPHONATES AND RISK OF OSTEONECROSIS OF JAW IN CANCER
PATIENTS: A META-ANALYSIS
Leung HW1, Chan A,L2, Ko J2
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OBJECTIVES: This meta-analysis aims to assess the potential risk of osteonecrosis
of jaw and bisphosphonate use in cancer patients . METHODS: The published
literature was systematically searched and reviewed usingMEDLINE (1950 through
July 2011), EMBASE (1980 through July 2011), and the Cochrane Central Register of
Controlled Trials (The Cochrane Library 2011 issue 1). Studies that included specific
risk estimates were pooled using a random-effects model. The bias and quality of
these studies were assessed with RevMan statistical software (version 5.0) and the
GRADEmethod of the Cochrane Collaboration. RESULTS: A total of 32 publications
met inclusion criteria, but only 9 studies that included 51580 subjects for analysis.
No randomized controlled clinical trials, meta-analysis or quality of life articles
were found that contained data for risks or prevalence of osteonecrosis. The results
of a meta-analysis that pooled data from 10 cohort studies indicated that the over-
all multivariable odds ratio and hazard ratio were 1.11 (95% CI: 0.15, 8.47 ) and 0.35,
23835 , respectively (95% CI 0.51 to 1.00; p  1.00), respectively. The risk of osteo-
necrosis associated with biophosphonate was statistically significant. The results
of the quality assessment of these studies indicated low scores using the GRADE
method. CONCLUSIONS: The uses of bisphosphonates is likely to be associated
with the increased risk of osteonecrosis of jaw in cancer patients.
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THE RELATIONSHIP OF FOLLOWING LIPID-LOWERING DRUGS USED WITH
ADJUVANT HORMONAL THERAPY IN BREAST CANCER WOMEN
Chang YC1, Lin SJ2
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2Kohsiung Medical University, Kaohsiung,
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OBJECTIVES: Extended adjuvant hormonal therapywith aromatase inhibitors (AIs)
or tamoxifen can both effectively reduce the recurrence of breast cancer, but the
potential of change lipid profile with AIs compared to tamoxifen was observed in
some clinical studies. The aim of this study was to evaluate whether the hormone
adjuvant therapywill increase the prescribing rate of lipid-lowering drugs (LLDs) in
breast cancer women. METHODS: A retrospective cohort study was conducted
using the National Health Insurance Research Database between January 1997 and
December 2008. The inclusion criteria were adult women who were newly diag-
nosed with breast cancer and without past history of hyperlipidemia or other can-
cer diseases between 1998 and 2008. The study endpoint was defined as emerging
of the first prescription of LLDs within the exposure period. Adjusted hazard ratio
(HR) for the first LLDs prescription was analyzed using multivariable Cox propor-
tional hazards regression model. RESULTS: There were 378, 1148 and 756 breast
cancer patients treated with AIs, tamoxifen and didn’t receive hormonal therapy,
respectively. Compared to the non-hormonal therapy cohort, the rate of prescrib-
ing LLDs was lower in patients who treated with tamoxifen after adjusted age and
comorbidity (HR0.68, [95% CI0.46-0.99]), and non-significantly increased in pa-
tients who treated with AIs (HR1.12 [95% CI0.65-1.91]). In addition, the prescrib-
ing LLDs rate between AIs treatment and treatment with tamoxifen was non-
significantly increased (HR1.41 [95% CI0.83-2.83]) in the head to head
comparison. CONCLUSIONS: Results from this study indicated that AIs does not
significantly increase the risk of prescribing LLDs compare to the patients without
hormonal therapy. In contract, the tamoxifen therapy was significantly reduced
the prescription rate of LLDs, thus tamoxifen might had potential benefit on lipid
metabolism.
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IMPROVEMENT OF THE 3RD GENERATION COLORECTAL CANCER GENE CHIP
Syu FK
Han-Ming Hospital, Changhua City, Taiwan
OBJECTIVES: Colorectal Cancer (CRC) has now become the second leading cause of
death in Taiwan, and is one of the cancers with highest incidence in women. Our
goal is to integrate comprehensive information to determine the relation between
omics and clinical pathology by a systematic biomedical approach and further
improve our third generation gene chips for higher sensitivity and specificity to-
ward colorectal cancer.METHODS: : One hundred and five patients colorectal can-
cer patients who had undergone curative surgical resection of colorectal cancer
were studied. The copy number for each SNP probe set taken from a tumor sample
was calculated by comparing the probe intensity to the reference probe intensity
from non-neoplastic tissue, and creating a list of the genome-wide copy number
data. RESULTS: Among 105 patients with a median follow-up period of 5.6 years
(range, 4.1-10.8 years), 23 developed early disease recurrence, whereas 82 did not.
Most of themweremale and less than 60 years (p0.044). Stage III, deeper invasive
tumor (T3 T4) and positive lymph node metastasis could be found seriously by
70.5%, 92.4%, and 68.6%, respectively. CEA, EV12B, ATP2A2, S100B, KLK7, TM4SF3,
and OLFM4 had copy number gains and high expression levels (P 0.05) in no
recurrence vs. recurrence. CONCLUSIONS: Patients less than 60 years were signif-
icantly risky to get early relapse in colorectal cancer. In comparison to traditional
colorectal cancer gene chip, we would weight higher on EV12B (RR 4.622, 95% CI
1.741-12.270, p0.001), ATP2A2 (RR 4.688, 95% CI 1.443-15.232, p0.006), and S100B
(RR 11.521, 95% CI 2.688-49.377, p0.0001).
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ROLE OF 5-ALPHA-REDUCTASE INHIBITORS, STATINS, ASPIRIN, NSAIDS ON
THE DEVELOPMENT OF PROSTATE CANCER IN BENIGN PROSTATIC
HYPERPLASIA PATIENTS-A POPULATION BASED STUDY
Chen SH, Wen YH, Huang YB, Chen JJ, Yang YH
Kaohsiung Medical University, Kaohsiung, Taiwan
OBJECTIVES: The 5-alpha-reductase inhibitors (5-ARIs), statins, aspirin and non-
steroidal anti-inflammatory drugs (NSAIDs) were previously reported to have pro-
tection effect for prostate cancer. The aim of this study was to simultaneously
investigate these drug effects on prostate cancer risk among benign prostatic hy-
perplasia (BPH) patients. METHODS: Newly diagnosed BPH patients (ICD-9-CM
code: 185 and A-code: A124) with at least one prescription of BPH medications
(5-ARIs, alpha-blockers) were identified from Taiwan Longitudinal Health Insur-
ance Database 2000 in 1998-2008. Drug usages of 5-ARIs, statins, aspirin, traditional
NSAIDs (tNSAIDs), and cyclooxygenase-2 (COX-2) selective inhibitors were com-
puted in terms of define daily dose (DDD), and were further categorized into high
and lose dose groups bymedians. The Cox regression was used to estimate hazard
ratios (HRs) for the occurrence of prostate cancer. Additional covariates in the
model included age, time-dependent covariates of drug usages and Charlson co-
morbidity score. RESULTS: There were 758 prostate cancers indicated from the
registry dataset for catastrophic illness patients from 41,955 BPH patients. The
analysis of all studied drugs showed significant protection HRs from univariate
analyses. After adjusting for covariates, the multivariable analysis showed signif-
icant protection effects on high dose of 5-ARIs (HR0.47, 95%CI 0.26-0.99), on high
dose of statins (HR0.56, 95%CI 0.38-0.83), on both low and high dose of tNSAIDs
(HR0.42, 95%CI 0.36-0.50; HR0.25, 95%CI 0.20-0.31), and on both low and high
dose of aspirin (HR0.73, 95%CI 0.60-0.88; HR0.34, 95%CI 0.26-0.45). The COX-2
selective inhibitors became not significant. CONCLUSIONS: The 5-ARIs, statins,
tNSAIDs, aspirin and COX-2 selective inhibitors have been separately investigated
their protection effects on the development of prostate cancer. Our results indi-
cated that the protection effects of 5-ARIs, statins, tNSAIDs and aspirin were inde-
pendently significant. In addition, the protection effect fromCOX-2 selective inhib-
itors was appeared to be confounded by other medication.
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OBJECTIVES: To evaluate the effect of Erythropoiesis stimulating agents (ESAs) use
on survival among colorectal cancer patients undergoing chemotherapy.
METHODS: This study was a nonconcurrent prospective cohort study using the
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2006 – 2008 Veterans Health Administration administrative data. There were 2,462
colorectal cancer patients receiving chemotherapy to estimate the effect of ESA on
mortality. Propensity score weighted Cox proportional hazard regressions were
performed. An interaction between ESAs and granulocyte colony stimulating fac-
tors (G-CSFs) was assessed. RESULTS: Overall, 12.7% of patients receiving chemo-
therapy in the cohort used ESAs at some time during the follow-up period. The
mean age of patients was 65.3 (standard deviation: 10.50) ranged from 22 to 97
years. The unadjusted Kaplan-Meier curves showed worse survival for ESA users
than non-users. There was no difference in survival between epoetin and darbe-
poetin. The estimated hazard ratio (HR) of ESA use for mortality was 2.045 (95% CI
 1.799 – 2.326) in a propensity score weighted model. The parameter estimate of
the interaction term between ESAs and G-CSFs was statistically significant
(-0.51574with standard error 0.20183, p0.0106). In the stratified analysis, the HR
was attenuated among the group of G-CSF users; HR  1.392; 95%CI  0.961, 2.017
for G-CSF users versusHR 2.327; 95%CI 2.027, 2.672 for non-users. This confirms
that there is an interaction between ESAs and G-CSFs. CONCLUSIONS: The use of
ESA was associated with decreased survival in colorectal cancer patients receiving
chemotherapy. There was no difference in the risks between ESA agents. The di-
rection of estimates was consistent with the results from the meta-analyses of
randomized clinical trials. Our study exclusively focused on colorectal cancer pa-
tients who were actively receiving chemotherapy and compared mortality rates
between ESA users and non-users in the study population. Our findings signifi-
cantly add to knowledge in oncology care in community practice.
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LENALIDOMIDE VERSUS BORTEZOMIB FOR TREATMENT OF
RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): A NUMBER NEEDED TO
TREAT (NNT) ANALYSIS
Kaura S1, Dranitsaris G2
1Celgene Corporation, Summit, NJ, USA, 2Augmentium Pharma Consulting, Toronto, ON, Canada
OBJECTIVES: Lenalidomide (LEN) and bortezomib (BORT) are effective drugs for the
treatment of refractory MM. Both agents have demonstrated an improvement in
disease response, progression free (PFS) and overall survival (OS) in the refractory
MM setting. NNT represents the number of patients that need to be treated with a
new intervention in order to have one additional patient deriving benefit, and is a
powerful approach that can be used to make sense of numerical results from clin-
ical trials. The NNT approach was used in the current study to compare LEN and
BOR in patients with relapsed MM. METHODS: The pivotal randomized trials for
LEN (Weber, Dimopoulos, 2007) and BORT (Richardson, 2005) were reviewed. A key
requirement for a NNT comparative analysis is that all outcomes be measured
against a comparable control. The NNT was then calculated for both agents with
respect to disease response and PFS at 12 months by taking the reciprocal of the
absolute differences in treatment effect between the experimental therapies and
the control group. RESULTS: For a disease response, theNNT for LEN and BORTwas
3 and 5 patients respectively; to have one additional patient achieving a disease
response. A difference in the NNT was also noted for PFS at 12 months; only 3
patients would need to be treated with LEN for an additional patient remaining
progression free compared to 9 with BORT. This is a relevant finding because it
suggests a 3 fold relative increase in clinical benefit in patients treat with LEN
compared to BORT. CONCLUSIONS: More patients treated with LEN are likely to
respond and to achieve a 12 month PFS than comparable patients treated with
BORT. Possible reasons for this effect include differences in the trial population,
extent of disease, and/or true differences in efficacy.
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OBJECTIVES: Breast cancer outcomes have improvedwith recent advancements in
diagnosis and treatment. Interest in breast cancer prevention is growing, andmore
clinical evidence is needed regarding the effects of preventive therapy, alone or in
combination, on breast cancer. METHODS: This was a nationwide case-control
analysis from the Taiwan National health Insurance Research Database. We ana-
lysed 16,847 female breast cancer cases among women older than 50 years who
were diagnosed between January 1, 2002, and December 31, 2008. A matched con-
trol group consisted of 50,460 matched subjects. Longitudinal exposure to angio-
tensin-converting enzyme (ACE) inhibitors, non-steroidal anti-inflammatory drugs
(NSAIDs), and aspirin was compared between women who had a first-time diag-
nosis of breast cancer and matched controls without a diagnosis of breast cancer.
RESULTS: The risk of breast cancer among patients taking both aspirin and ACEI
decreased as the ACEI dose increased. Among patients receiving between 28-364
cumulative defined daily doses (cDDD) of aspirin, the adjusted ORs were 0.97 (0.90-
1.06), 0.91 (0.82-1.03) and 0.79 (0.68-0.92) for women taking ACEI for 0-27, 28-364,
and 365 cDDD, respectively. Among women receiving 365 cDDD of aspirin, the
adjusted ORs were 0.91 (0.80-1.03), 0.81 (0.70-0.94) and 0.81 (0.71-0.92) as the ACEI
dose increased, respectively. Women taking non-aspirin NSAIDs along with ACEI
had the same finding. Amongwomen taking 28 - 364 cDDD of NSAIDs, the adjusted
ORs were 0.85 (0.81-0.89), 0.87 (0.81-0.94) and 0.80 (0.73-0.88) ; for women receiving
365 cDDD of NSAIDs, the adjusted ORs were 0.68 (0.62-0.74), 0.61 (0.53-0.70) and
0.60 (0.52-0.70) as the ACEI dose increased, respectively. CONCLUSIONS: The find-
ings of this nationwide case-control analysis support the hypothesis that ACE in-
hibitors enhance the antitumor effect of cyclooxygenase (COX) inhibitors on breast
cancer. There was no statistically significant association between use of any ACE
inhibitor alone and breast cancer rates.
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THE ASSOCIATION BETWEEN ANDROGEN-DEPRIVATION THERAPY IN
PROSTATE CANCER AND CARDIOVASCULAR RISK IN TAIWAN: A POPULATION-
BASED COHORT STUDY
Tsai YH, Tsai TR
Kaohsiung Medical University, Kaohsiung, Taiwan
OBJECTIVES: Some observational studies indicate that androgen deprivation ther-
apy (ADT) for prostate cancer (PC) is associated with cardiovascular disease. How-
ever, the results are not currently identified in the Asian populations. We assessed
whether ADT is associated with cardiovascular disease, using a population-based
dataset. METHODS: This cohort study used data sourced from the Longitudinal
Health Insurance Database. A total of 693 subjects who were newly diagnosed PC
between January 1, 1998 and December 31, 2007, and followed until December 31,
2009. There were 313 subjects received ADT (GnRH agonists, oral antiandrogen, the
combination of the two, orchiectomy). Cox proportional hazardsmodels were used
to assess whether ADT was associated with coronary heart disease (CHD), stroke,
or heart failure, after adjusting for age, location, socioeconomic status, co-morbid-
ities, drug, year of diagnosis and type of procedure. RESULTS: In survival analysis,
ADT use was not associated with an increased risk of CHD (adjusted hazard ratio
[aHR]  1.08, 95% CI  0.747 to 1.557), stroke (aHR  0.97, 95% CI  0.661 to 1.414),
heart failure (aHR  1.22, 95% CI  0.791 to 1.875). GnRH agonist and combination
oral antiandrogen were both not associated with any outcomes. Low cumulative
dose (0-53 DDD) of antiandrogen was associated with significantly increased risks
of CHD (aHR  3.91, 95% CI  1.257 to 12.141). Among patients not treated with
radical prostatectomy, GnRH agonist use was associated with increased risk of
heart failure (aHR  2.32, 95% CI  1.010 to 5.324). Among patients with CHD,
combined therapy was associated with increased risk of heart failure (aHR  2.71,
95% CI 1.078 to 6.807). CONCLUSIONS: Low cumulative dose of antiandrogenwas
associated with increased risks of CHD. The use of combined therapy appears to be
associated with increased risk of heart failure in patients with CHD.
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OBJECTIVES: Venous thromboembolism (VTE) is a common complication among
cancer patients which results in significant morbidity and mortality. Although the
need to optimize the prevention of VTE has been recognized inWestern countries,
the understanding of the epidemiology of VTE in Asian countries remains limited.
The goal of this population-based observational study is to explore the epidemiol-
ogy and clinical profiles of VTE among cancer patients in Taiwan.METHODS:Using
Taiwan’s National Health Insurance Research Database, we identified newly diag-
nosed cancer patients between 2001 and 2010. Study outcome was defined as a
hospitalization with VTE diagnosis during or after the cancer diagnosis date. To
verify the accuracy of VTE diagnosis, patients must have received subcutaneous or
intravenous anticoagulants, surgical thromboectomy, angioplasty or insertion of
inferior vena cava filter during the VTE hospitalization. The incidence rate of VTE
for the entire study cohort and subgroups of patients categorized by sites of cancer
was estimated. RESULTS: Among 46,061 cancer patients, 555 (2.7 per 1000 patient-
year) patients had VTE admission (438 (78.92%) venous thrombosis, 91 (16.40%)
pulmonary embolism (PE) and 26 (4.68%) with concomitant PE and venous throm-
bosis) during or after the cancer diagnosis date. Sites of cancer with the highest
rates of VTE were myeloma, pancreas, liver, lung, and ovary, with incidence rates
were 5.52, 5.49, 4.67, 4.53, and 4.42 per 1000 patient-year, respectively. Approxi-
mately one-fifth (19.46%, n108) of VTE admission was occurred at the cancer
diagnosis date. Cumulative occurrence of VTE within 1, 3, 6, and 12 months were
26.49%, 40.18%, 49.01%, and 59.28%, respectively. CONCLUSIONS: Although the
incidence of cancer-related VTE among Taiwanese is lower than Caucasians pop-
ulation, it is not rare in specific cancer such asmyeloma, pancreas and liver cancer.
Most VTE occurred within 1 year after cancer diagnosis. Prevention of VTE may be
optimized in higher-risk patients.
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RISK OF BREAST CANCER AND STATINS: A POPULATION-BASED NESTED CASE-
CONTROL STUDY IN CHINESE POPULATION
Chan AL1, Leung HW2, Wang JJ3
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OBJECTIVES: Statin use has been increasing, especially middle-aged and elderly
patients with chronic disease, who use them continuously in Taiwan. Studies con-
ducted in the United States did not report an association between the use of statins
and breast cancer; to the best of our knowledge, no studies of a potential associa-
tion have been conducted in a Chinese population. We analyzed data from the
National Health Insurance Research Database in Taiwan to evaluate the associa-
tion between statin use and breast cancer risk. METHODS: This is a population-
based nested case-control study used data from the Taiwan National Health Insur-
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